companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2019
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2019. In 2019, the company reported a net result of DKK -398,000 compared with DKK 189,000 the year before. Equity amounted to DKK 8,924,000. The solvency ratio was 97.4%.
- Profit/Loss
- -398,000 kr.
- Equity
- 8,924,000 kr.
- Total Assets
- 9,160,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | - | -398 t. | 8.9 mio. | - |
| 2018 | - | - | 189 t. | 9.3 mio. | - |
| 2017 | - | - | -775 t. | 9.1 mio. | - |
| 2016 | - | - | -407 t. | 9.9 mio. | - |
| 2015 | 219.3 mio. | - | 803 t. | 10.3 mio. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
Novo Nordisk Invest 4 A/S has published its annual report for 2018. The net result was DKK 189,000.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.